Paclitaxel
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1992
- First approval year
- 1992
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Paclitaxel
- Molecular weight
- 853.92
- Structure (SMILES)
- CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O
- abraxane
- Abraxane
- apealea
- Apealea
- apexelsin
- Apexelsin
- naveruclif
- Naveruclif
- pacitaxel
- Pacitaxel
- paclitaxel
- Paclitaxel
- paclitaxel component of abi 007
- Paclitaxel component of abi 007
- paclitaxel component of abraxane
- Paclitaxel component of abraxane
- paclitaxel component of nab
- Paclitaxel component of nab-
- paclitaxel component of oraxol
- Paclitaxel component of oraxol
- paxene
- Paxene
- pazenir
- Pazenir
- taxol
And 5 more, listed on the interactive page.
- .BETA.-(BENZOYLAMINO)- .ALPHA.-HYDROXY-
- (-)-paclitaxel
- (-)-PACLITAXEL
- [2AR- [2A.ALPHA.,4.BETA.,4A.BETA.,6.BETA.,9.ALPHA.(ALPHA. R*,.BETA.S*),11.ALPHA.,12.ALPHA.,12A.ALPHA.,12B.ALPHA.]]-TAX-11-EN-9-ONE
- 10 beta 13 alpha hexahydroxy
- 10.BETA.,13.ALPHA.- HEXAHYDROXY-
- 2ar 2a alpha 4 beta 4a beta 6 beta 9 alpha alpha r beta s 11 alpha 12 alpha 12a alpha 12b alpha tax 11 en 9 one
- 4 10 diacetate 2 benzoate 13 ester with 2r 3s n benzoyl 3 phenylisoserine
- 4,10-DIACETATE 2- BENZOATE,13-ESTER WITH (2R,3S)-N-BENZOYL-3-PHENYLISOSERINE
- 5 beta 20 epoxy 1 2 alpha 4 7 beta
- 5.BETA.,20-EPOXY-1,2.ALPHA.,4,7.BETA.
- 6 12b bis acetyl oxy 12 benzoyloxy 2a 3 4 4a 5 6 9 10 11 12 12a 12b dodecahydro 4 11 dihydroxy 4a 8 13 13 tetramethyl 5 oxo 7 11 methano 1h cyclodeca 3 4 benz 1 2 b oxet 9 yl ester
- 6,12B-BIS(ACETYL OXY)-12-(BENZOYLOXY)- 2A,3,4,4A,5,6,9,10,11,12,12A,12B,- DODECAHYDRO-4,11- DIHYDROXY-4A,8,13,13-TETRAMETHYL-5-OXO- 7,11-METHANO- 1H-CYCLODECA[3,4]BENZ[1,2-B]OXET-9-YL ESTER
- 7 epi taxol
- 7 EPI TAXOL
- 7-EPI-TAXOL
- abemaciclib paclitaxel
- abi 007
- abi 007 component paclitaxel
- ABI 007 COMPONENT PACLITAXEL
- ABI-007
- ABI-007 (Abraxane)
- ABI-007 (Abraxane®)
- ABI-007 COMPONENT PACLITAXEL
- ABI-007(Abraxane)
And 264 more, listed on the interactive page.
- ATC classification codes
- L01CD01
Sources for recorded values
- CAS registry numbers
- 33069-62-4
- ChEMBL ID
- CHEMBL428647
- InChIKey
- RCINICONZNJXQF-MZXODVADSA-N
- PubChem compound IDs
- 36314
- RxNorm IDs (RxCUI)
- 56946
- FDA ingredient codes (UNII)
- P88XT4IS4D
- Applicant
- BRISTOL-MYERS
- Approval date
- 7 Jan 2005
- Application number
- NDA021660
- Status
- Authorised
- Status date
- 11 Jan 2008
- Authorisation date
- 11 Jan 2008
- Approved indications
- Abraxane monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated. Abraxane in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas. Abraxane in combination with carboplatin is indicated for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.
- Product number
- EMEA/H/C/000778
- Authorisation holder
- Bristol-Myers Squibb Pharma EEIG
- Priority medicines scheme
- No
- Generic
- No
- Biosimilar
- No
- Generic medicines
- 3
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- No
- Accelerated assessment
- No
- Exceptional circumstances
- No
Therapeutic areas
- Breast Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Pancreatic Neoplasms
European medicines record
- Patents
- 14
- Designations
- 4
- Earliest recorded loss of exclusivity
- 12 Jul 2034
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- Yes
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Boxed warning
- Yes
- Pharmacology name
- paclitaxel
- Type
- Natural product
- Drug name stem
- -taxel
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Parenteral
- Action
- Agonist
- Action type
- Agonist
- Target
- Pregnane X receptor
- Gene symbol
- NR1I2
- Protein identifier
- O75469
- Median affinity
- 5.3
- Affinity units
- pEC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- tubulin beta class I
- Gene symbol
- TUBB
- Protein identifier
- P07437
- Median affinity
- 8.05
- Affinity units
- pEC50
- Primary target
- Yes
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- P04350
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- P07437
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- P0DPH7
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- P68363
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- P68366
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- P68371
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- Q13509
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- Q13885
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- Q3ZCM7
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- Q6PEY2
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- Q71U36
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- Q9BQE3
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- Q9BUF5
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- Q9BVA1
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Protein identifier
- Q9H4B7
Open Targets mechanisms
- Mechanism
- Tubulin inhibitor
- Action type
- Inhibitor
- Target
- Tubulin
- Action type
- Agonist
- Gene symbol
- NR1I2
- Protein identifier
- O75469
- Organism
- Homo sapiens
- Target development level
- Chemical evidence
- Action type
- Inhibitor
- Gene symbol
- TUBB
- Protein identifier
- P07437
- Organism
- Homo sapiens
- Target development level
- Clinical
- Action type
- Inhibitor
- Gene symbol
- TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8
- Protein identifier
- P07437|Q9H4B7|Q13885|Q9BVA1|Q13509|P04350|P68371|Q9BUF5|Q3ZCM7
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Leukemia, Lymphocytic, Chronic, B-Cell
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000095
- Subject identifier
- D015451
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000178
- Subject identifier
- D013274
- Condition
- HIV Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000180
- Subject identifier
- D015658
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000181
- Subject identifier
- D002294
- Condition
- Carcinoma, Hepatocellular
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000182
- Subject identifier
- D006528
- Condition
- Hodgkin Disease
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000183
- Subject identifier
- D006689
- Condition
- Squamous Cell Carcinoma of Head and Neck
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000199
- Subject identifier
- D000077195
- Condition
- Adenocarcinoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000228
- Subject identifier
- D000230
- Condition
- Prostatic Hyperplasia
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000284
- Subject identifier
- D011470
- Condition
- Urinary Bladder Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000294
- Subject identifier
- D001749
- Condition
- Breast Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000305
- Subject identifier
- D001943
- Condition
- Adenocarcinoma, Bronchiolo-Alveolar
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000308
- Subject identifier
- D002282
- Condition
- Carcinoma
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000313
- Subject identifier
- D002277
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000365
- Subject identifier
- D015179
- Condition
- Melanoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000389
- Subject identifier
- D008545
- Condition
- Carcinoma, Intraductal, Noninfiltrating
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000432
- Subject identifier
- D002285
- Condition
- Carcinoma, Endometrioid
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000466
- Subject identifier
- D018269
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000503
- Subject identifier
- D013274
- Condition
- Neoplasms, Germ Cell and Embryonal
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000514
- Subject identifier
- D009373
- Condition
- Glioblastoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000519
- Subject identifier
- D005909
- Condition
- Ischemia
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000556
- Subject identifier
- D007511
- Condition
- Sarcoma, Kaposi
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000558
- Subject identifier
- D012514
- Condition
- Leukemia
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000565
- Subject identifier
- D007938
- Condition
- Adenocarcinoma of Lung
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000571
- Subject identifier
- D000077192
- Condition
- Lymphoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
And 144 more, listed on the interactive page.
- Condition identifier
- EFO_0000178
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000180
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000181
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000182
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000228
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000284
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000305
- Condition identifier
- EFO_0000313
- Condition identifier
- EFO_0000365
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000389
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000409
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000503
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000514
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000556
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000558
- Condition identifier
- EFO_0000565
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000571
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000574
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0000673
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000676
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000685
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000691
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000702
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000707
- Highest recorded phase
- 3
And 337 more, listed on the interactive page.
- Warning
- Black Box Warning
- Effect
- dermatological toxicity
- Warning
- Black Box Warning
- Effect
- hematological toxicity
- Warning
- Black Box Warning
- Effect
- immune system toxicity
- Warning
- Black Box Warning
- Effect
- vascular toxicity
- Warning
- Black Box Warning
- Effect
- dermatological toxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- hematological toxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- immune system toxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- vascular toxicity
- Country
- United States
- Event
- anaemia
- Reports
- 3,073
- Reporting signal score
- 1,755.82
- Event
- bone marrow failure
- Reports
- 769
- Reporting signal score
- 797.195
- Event
- breast cancer metastatic
- Reports
- 282
- Reporting signal score
- 531.572
- Event
- dehydration
- Reports
- 1,619
- Reporting signal score
- 820.246
- Event
- diarrhoea
- Reports
- 4,671
- Reporting signal score
- 1,330.37
- Event
- disease progression
- Reports
- 1,602
- Reporting signal score
- 1,114.73
- Event
- dyspnoea
- Reports
- 2,564
- Reporting signal score
- 586.636
- Event
- febrile neutropenia
- Reports
- 2,797
- Reporting signal score
- 3,829.09
- Event
- flushing
- Reports
- 1,124
- Reporting signal score
- 723.774
- Event
- general physical health deterioration
- Reports
- 792
- Reporting signal score
- 515.311
- Event
- leukopenia
- Reports
- 1,417
- Reporting signal score
- 1,264.24
- Event
- malignant neoplasm progression
- Reports
- 1,825
- Reporting signal score
- 2,039.67
- Event
- metastases to bone
- Reports
- 612
- Reporting signal score
- 938.983
- Event
- metastases to liver
- Reports
- 625
- Reporting signal score
- 981.574
- Event
- mucosal inflammation
- Reports
- 1,133
- Reporting signal score
- 1,433
- Event
- myelosuppression
- Reports
- 852
- Reporting signal score
- 1,574.5
- Event
- neuropathy peripheral
- Reports
- 2,045
- Reporting signal score
- 1,799.48
- Event
- neutropenia
- Reports
- 3,655
- Reporting signal score
- 3,426.48
- Event
- neutrophil count decreased
- Reports
- 1,142
- Reporting signal score
- 1,159.59
- Event
- palmar-plantar erythrodysaesthesia syndrome
- Reports
- 821
- Reporting signal score
- 940.561
- Event
- peripheral sensory neuropathy
- Reports
- 518
- Reporting signal score
- 917.703
- Event
- pneumonitis
- Reports
- 486
- Reporting signal score
- 495.012
- Event
- polyneuropathy
- Reports
- 538
- Reporting signal score
- 720.725
- Event
- thrombocytopenia
- Reports
- 1,709
- Reporting signal score
- 739.881
- NCT00001272
- NCT00001426
- NCT00069901
- NCT00191646
- NCT00653952
- NCT00919984
- NCT01121406
- NCT01279291
- NCT01608009
- NCT01616303
- NCT02107937
- NCT02470585
- NCT02903004
- NCT03314740
- NCT03394885
- NCT03574779
- NCT04561817
- NCT04711161
- NCT05613088
- NCT00001383
- NCT00001384
- NCT00001498
- NCT00002627
- NCT00002628
- NCT00002662
And 2,233 more, listed on the interactive page.
- Dose
- 260 mg/m2
- Route
- Intravenous
- How often
- Every 3 weeks
- Hydrogen bond acceptors
- 14
- Hydrogen bond donors
- 4
- Polar surface area
- 221.29
- Calculated partition coefficient (ALogP)
- 3.74
- Calculated partition coefficient (XLogP)
- 2.5
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 2
- Rotatable bonds
- 10
- Heavy atoms
- 62
- Molecular formula
- C47H51NO14
- Monoisotopic mass
- 853.33095530
- Natural product
- Yes
- 0480-3290
- 0517-4300
- 0703-3213
- 0703-3216
- 0703-3217
- 0703-3218
- 0781-3531
- 16714-137
- 23155-882
- 23155-883
- 23155-884
- 25021-255
- 46708-620
- 46708-621
- 46708-622
- 61703-015
- 61703-342
- 62332-620
- 62332-621
- 62332-622
- 63323-763
- 67457-937
- 68001-516
- 68001-651
- 68001-705
And 16 more, listed on the interactive page.
- Recorded assays
- 18,072
- Active assays
- 4,947
- Confirmatory
- Other
- Screening
- Summary
- Antineoplastic Agents, Phytogenic
- Tubulin Modulators
These details could not be displayed.
Related records
Trials (3,860)
- 'ADVANCE' (A Pilot Trial)
- "Curcumin" in Combination With Chemotherapy in Advanced Breast Cancer
- "Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients"
- [18F]FLT PET/CT in Rb+ Metastatic Breast Cancer
- [18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer
- 17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor
- 1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer
- 2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab
- 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
- 3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer
- 4 Versus 6 Courses of Adjuvant Chemotherapy in LACC Patients Previously Treated With NACT Plus Radical Surgery
- 6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors
- 8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer
- 9-ING-41 in Patients With Advanced Cancers
- 9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma
- A 2-part Phase 1/2 Open-label Trial on ODM-212
- A Biomarker Study in Patients With HER2-negative Metastatic Breast Cancer Treated With Bevacizumab and Paclitaxel
- A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC
- A Clinical Research of NK Cell Infusion Combined With Chemotherapy in the Treatment of Non-small Cell Lung Cancer
- A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer
Approved for (16)
- Breast cancer
- Breast carcinoma
- Breast neoplasm
- Cancer
- Carcinoma
- Exocrine pancreatic carcinoma
- HER2 positive breast carcinoma
- Kaposi's sarcoma
- Malignant pancreatic neoplasm
- Neoplasm
- Non-small cell lung carcinoma
- Ovarian cancer
- Ovarian carcinoma
- Ovarian neoplasm
- Pancreatic neoplasm
- Undifferentiated carcinoma
In development for (152)
- Actinic keratosis Phase 2
- Adenocarcinoma Phase 3
- Adrenal cortex carcinoma Phase 2
- Allergic disease Phase 3
- Anemia Phase 3
- Angiosarcoma Phase 2
- Anus cancer Phase 1
- B-cell chronic lymphocytic leukemia Phase 1
- Benign prostatic hyperplasia Phase 2
- Biliary tract cancer Phase 3
- Bone cancer Phase 2
- Bone neoplasm Phase 2
- Brain neoplasm Phase 1
- Breast carcinoma in situ Phase 2
- Breast ductal adenocarcinoma Phase 2
- Carcinoid tumor Phase 1
- Carcinoma of esophagus Phase 3
- Central nervous system germ cell tumor Phase 2
- Central nervous system neoplasm Phase 2
- Cervical adenocarcinoma Phase 3
Other linked conditions (3)
- Lip and oral cavity carcinoma
- Skin squamous cell carcinoma
- Tongue neoplasm
Targets (15)
- TUBA1A Tubulin inhibitor
- TUBA1B Tubulin inhibitor
- TUBA1C Tubulin inhibitor
- TUBA3C Tubulin inhibitor
- TUBA3E Tubulin inhibitor
- TUBA4A Tubulin inhibitor
- TUBB Tubulin inhibitor
- TUBB1 Tubulin inhibitor
- TUBB2A Tubulin inhibitor
- TUBB2B Tubulin inhibitor
- TUBB3 Tubulin inhibitor
- TUBB4A Tubulin inhibitor
- TUBB4B Tubulin inhibitor
- TUBB6 Tubulin inhibitor
- TUBB8 Tubulin inhibitor